Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion

• Published in: Acta neuropathologica communications Vol. 12; no. 1; p. 42
• Main Authors: Andreiuolo, Felipe, Ferrone, Christina K, Rajan, Sharika, Perry, Arie, Guney, Ekin, Cham, Elaine, Giannini, Caterina, Toland, Angus, Willard, Nicholas, de Souza, Andrea Silveira, Dazelle, Karen, Chung, Hye-Jung, Singh, Omkar, Conway, Kyle, Coley, Nicholas, Dampier, Christopher, Abdullaev, Zied, Pratt, Drew, Cimino, Patrick J, Quezado, Martha, Aldape, Kenneth
• Format: Journal Article
• Language: English
• Published: England BioMed Central 18-03-2024; BMC
• Subjects: Brain Neoplasms - pathology; BRD4::LEUTX; Bromodomain Containing Proteins; Cell Cycle Proteins; Central Nervous System Neoplasms - genetics; Central Nervous System Neoplasms - pathology; DNA methylation; Embryonal tumor; Forkhead Transcription Factors; Gene expression; Homeodomain Proteins; Humans; Methylation; Neoplasms, Germ Cell and Embryonal - genetics; Neuroblastoma; Nuclear Proteins - genetics; Pediatrics; Transcription Factors - genetics; Tumors; United States > US; Colorado; California; Embryonal tumor; Methylation; BRD4::LEUTX
• ISSN: 2051-5960; 2051-5960
• DOI: 10.1186/s40478-024-01746-7

Central nervous system (CNS) embryonal tumors are a heterogeneous group of high-grade malignancies, and the increasing clinical use of methylation profiling and next-generation sequencing has led to the identification of molecularly distinct subtypes. One proposed tumor type, CNS tumor with BRD4::LEUTX fusion, has been described. As only a few CNS tumors with BRD4::LEUTX fusions have been described, we herein characterize a cohort of 9 such cases (4 new, 5 previously published) to further describe their clinicopathologic and molecular features. We demonstrate that CNS embryonal tumor with BRD4::LEUTX fusion comprises a well-defined methylation class/cluster. We find that patients are young (4 years or younger), with large tumors at variable locations, and frequently with evidence of leptomeningeal/cerebrospinal fluid (CSF) dissemination. Histologically, tumors were highly cellular with high-grade embryonal features. Immunohistochemically, 5/5 cases showed synaptophysin and 4/5 showed OLIG2 expression, thus overlapping with CNS neuroblastoma, FOXR2-activated. DNA copy number profiles were generally flat; however, two tumors had chromosome 1q gains. No recurring genomic changes, besides the presence of the fusion, were found. The LEUTX portion of the fusion transcript was constant in all cases assessed, while the BRD4 portion varied but included a domain with proto-oncogenic activity in all cases. Two patients with clinical follow up available had tumors with excellent response to chemotherapy. Two of our patients were alive without evidence of recurrence or progression after gross total resection and chemotherapy at 16 and 33 months. One patient relapsed, and the last of our four patients died of disease one month after diagnosis. Overall, this case series provides additional evidence for this as a distinct tumor type defined by the presence of a specific fusion as well as a distinct DNA methylation signature. Studies on larger series are required to further characterize these tumors.